Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
Publication date: Available online 5 February 2020Source: The Lancet HIVAuthor(s): Andrew N Phillips, Loveleen Bansi-Matharu, Francois Venter, Diane Havlir, Anton Pozniak, Daniel R Kuritzkes, Annemarie Wensing, Jens D Lundgren, Deenan Pillay, John Mellors, Valentina Cambiano, Andreas Jahn, Tsitsi Apollo, Owen Mugurungi, David Ripin, Juliana Da Silva, Elliot Raizes, Nathan Ford, George K Siberry, Ravindra K GuptaSummaryBackgroundThe integrase inhibitor dolutegravir is being considered in several countries in sub-Saharan Africa instead of efavirenz for people initiating antiretroviral therapy (ART) because of superior tolera...
Source: The Lancet HIV - February 6, 2020 Category: Infectious Diseases Source Type: research
More evidence for dolutegravir as first-line ART for all
Publication date: Available online 5 February 2020Source: The Lancet HIVAuthor(s): Janne Estill, Barbara Bertisch (Source: The Lancet HIV)
Source: The Lancet HIV - February 6, 2020 Category: Infectious Diseases Source Type: research
Time to PrEP for zero HIV transmissions in the UK?
Publication date: Available online 4 February 2020Source: The Lancet HIVAuthor(s): The Lancet HIV (Source: The Lancet HIV)
Source: The Lancet HIV - February 5, 2020 Category: Infectious Diseases Source Type: research
False information on PrEP in direct-to-consumer advertising
Publication date: Available online 4 February 2020Source: The Lancet HIVAuthor(s): Amy S Nunn, William C Goedel, Courtney E Gomillia, Cassandra Sutten Coats, Rupa R Patel, Matthew J Murphy, Christina T Chu, Philip A Chan, Leandro A Mena (Source: The Lancet HIV)
Source: The Lancet HIV - February 5, 2020 Category: Infectious Diseases Source Type: research
Understanding HIV risk and vulnerability among cisgender men with transgender partners
Publication date: Available online 4 February 2020Source: The Lancet HIVAuthor(s): Tonia Poteat, Mannat Malik, Andrea L Wirtz, Erin E Cooney, Sari ReisnerSummaryIn the HIV pandemic, cisgender (ie, non-transgender) men with transgender partners are an underserved population. Complexities of sexuality and gender affect HIV vulnerability for this group, including not identifying with conventional sexual orientation categories (eg, bisexual, heterosexual, or gay) and having attractions based on gender role or expression rather than genital anatomy. Only one HIV prevention interventional study in this population was identified,...
Source: The Lancet HIV - February 5, 2020 Category: Infectious Diseases Source Type: research
The syndemic threat of food insecurity and HIV
Publication date: February 2020Source: The Lancet HIV, Volume 7, Issue 2Author(s): The Lancet HIV (Source: The Lancet HIV)
Source: The Lancet HIV - February 4, 2020 Category: Infectious Diseases Source Type: research
On-demand PrEP efficacy: forgiveness or timely dosing
Publication date: February 2020Source: The Lancet HIV, Volume 7, Issue 2Author(s): Jean-Jacques Parienti (Source: The Lancet HIV)
Source: The Lancet HIV - February 4, 2020 Category: Infectious Diseases Source Type: research
Antiretroviral resistance and management after pre-exposure to prophylaxis
Publication date: February 2020Source: The Lancet HIV, Volume 7, Issue 2Author(s): Victoria Tittle, Marta Boffito, Alan McOwan, Gary Whitlock, Dean Street Collaborative Group (Source: The Lancet HIV)
Source: The Lancet HIV - February 4, 2020 Category: Infectious Diseases Source Type: research
Conditional economic incentives to improve HIV prevention
Publication date: February 2020Source: The Lancet HIV, Volume 7, Issue 2Author(s): Mark K U Pasayan, Adeyinka A Alabi, Douglas F Nixon (Source: The Lancet HIV)
Source: The Lancet HIV - February 4, 2020 Category: Infectious Diseases Source Type: research
PrEP use falling short in African American and Hispanic MSM
Publication date: February 2020Source: The Lancet HIV, Volume 7, Issue 2Author(s): Tony Kirby (Source: The Lancet HIV)
Source: The Lancet HIV - February 4, 2020 Category: Infectious Diseases Source Type: research
Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings
Publication date: Available online 31 January 2020Source: The Lancet HIVAuthor(s): Cheryl Hendrickson, Lawrence Long, David van de Vijver, Charles Boucher, Heidi O'Bra, Cassidy W Claassen, Mwansa Njelesani, Crispin Moyo, Daliso B Mumba, Hasina Subedar, Lloyd Mulenga, Sydney Rosen, Brooke E NicholsSummaryAlthough large-scale provision of HIV pre-exposure prophylaxis (PrEP) is gaining momentum, no systematic method to evaluate or compare the effectiveness of different scale-up strategies in real-world settings exists. To date, estimating the effectiveness of PrEP has relied on clinical trials or mathematical models. We propo...
Source: The Lancet HIV - February 1, 2020 Category: Infectious Diseases Source Type: research
Correction to Lancet HIV 2019; 6: e71–72
Publication date: Available online 28 January 2020Source: The Lancet HIVAuthor(s): (Source: The Lancet HIV)
Source: The Lancet HIV - January 29, 2020 Category: Infectious Diseases Source Type: research
Correction to Lancet HIV 2019; 6: e105–15
Publication date: Available online 28 January 2020Source: The Lancet HIVAuthor(s): (Source: The Lancet HIV)
Source: The Lancet HIV - January 29, 2020 Category: Infectious Diseases Source Type: research
Responding to expanding HIV epidemics in Cebu, Philippines
Publication date: Available online 16 January 2020Source: The Lancet HIVAuthor(s): Nicholas A Medland, Peter Banys, Van Phillip Baton, Johann Nadela, Lisa Maher, Ilya Tac-An (Source: The Lancet HIV)
Source: The Lancet HIV - January 17, 2020 Category: Infectious Diseases Source Type: research
Time, population mobility, and HIV transmission
Publication date: Available online 14 January 2020Source: The Lancet HIVAuthor(s): Susan Cassels (Source: The Lancet HIV)
Source: The Lancet HIV - January 15, 2020 Category: Infectious Diseases Source Type: research
